INTRODUCTION

Celiac disease is an autoimmune disorder involving the multisystem of the body, which is triggered by an immune reaction to a gluten-containing diet occurring in genetically predisposed individuals (HLA-DQ2/DQ8). Clinical gastrointestinal manifestations of celiac disease, such as chronic diarrhea, malnutrition, and abdominal distention, are usually non-specific symptoms. For the diagnosis of celiac disease in adults, a combination of celiac disease serology testing and duodenal biopsy sampling is performed. According to a recent clinical practice guideline on diagnosis and monitoring of celiac disease by the American Gastroenterological Association, serology testing such as that of tissue transglutaminase IgA, deaminated gliadin IgA, and endomysial IgA antibody (Abs) is an essential component of the detection and diagnosis of celiac disease. It has been reported that the prevalence of celiac disease is about 1.0% of the general population globally. Meanwhile, in Asian countries, it has been reported that celiac disease is extremely uncommon in Asian populations; however, with the aid of serological biomarkers such as tissue transglutaminase IgA, deaminated gliadin IgA, and endomysial IgA Ab, it has been shown that celiac disease is both a common and an often underdiagnosed disorder in Asia.

In South Korea, there have been few case reports of celiac disease patients. However, to the best of our knowledge, there has been no information regarding the test utilization of diagnostic assays for celiac disease in Korea. Therefore, for the first time, in this study we aimed to investigate the test utilization of serological
bimerkers including tissue transglutaminase IgA, deaminated gliadin IgA and IgG, and endomysial IgA Ab assays in South Korea.

2 | MATERIALS AND METHODS

We retrospectively reviewed data for tissue transglutaminase IgA, deaminated gliadin IgA and IgG, and endomysial IgA Ab assays between January 1, 2011, and June 30, 2020, through Green Cross Laboratories’ information system. Green Cross Laboratories, one of the largest referral clinical laboratories in South Korea, provides clinical specimen analytical services for various types of assays including esoteric laboratory tests nation-wide. All data were anonymized prior to being adopted for statistical analysis. The numbers and percentages of each considered test were presented in this study. The protocol of this study was approved by the institutional review board (IRB) of Green Cross Laboratories (GCL-2020-1043). A waiver of informed consent was approved by the IRB since the use of a waiver would not adversely affect the rights or welfare of the study subjects because the study was retrospective and involved minimal risk to the subjects.

3 | RESULTS

During a nine-year-and-six-month study period, overall 307,322,606 clinical tests were requested from different clinical settings, such as local clinics, hospitals, university hospitals, and tertiary medical centers. Among them, only 90 tissue transglutaminase IgA, 25 deaminated gliadin IgA, 15 deaminated gliadin IgG, and 64 endomysial IgA Ab tests from 152 adult patients (79 Korean and 73 foreign patients) were requested. Among 79 Koreans, two patients obtained results for all four serologic assays, two patients had tissue transglutaminase IgA, deaminated gliadin IgA, and endomysial IgA Ab results, three patients had tissue transglutaminase IgA, deaminated gliadin IgA and IgG Ab results, and six patients had tissue transglutaminase IgA and endomysial IgA Ab results. Only 58 transglutaminase IgA, 22 deaminated gliadin IgA, 12 deaminated gliadin IgG, and 16 endomysial IgA Ab tests were performed in 79 Korean patients. Among all 79 Korean patients, no patients had positive results for any of the four assays except for one (1.3%) woman who had a positive tissue transglutaminase IgA Ab (4 U/ml, reference for negative result ≤4 U/ml). During the study period, all four assay tests were referred to Quest Diagnostics in the United States because clinical requests for these tests rarely occur in Korea and no clinical laboratory in South Korea provided analytical services for these tests.

4 | DISCUSSION

Considering the annual number of clinical sample requests to Green Cross Laboratories, test utilization of these assays was extremely rare (<0.0001% for all clinical tests during the study period). This underutilization may be one of the main causes for the low disease prevalence and incidence of celiac disease in Korea.

In this study, one patient had a positive tissue transglutaminase IgA Ab result, though it showed a low titer value (<2 times the upper limit of normal). This result needed to be confirmed as celiac disease using intestinal biopsy. Unfortunately, clinical information is limited for further diagnostic approaches for celiac disease including biopsy in this patient.

It has been reported that the prevalence and incidence of celiac disease in Korea is extremely rare (Table 1), with the hypothesis that the prevalence of at-risk patients with a genetic predisposition (HLA-DQ2/DQ8) is low and a relatively low intake of foods containing gluten, which may lead physicians to overlook celiac disease during routine clinical practice and medical training. However, another important factor for the prevalence and incidence of celiac disease in Korea is the applicability of serologic assays to discover patients. In Korea, assays performed in overseas laboratories are not reimbursed by the single government payer and require out-of-pocket payment. Due to underutilization, clinical laboratories in Korea could not perform these serologic tests and have referred them to overseas laboratories. This has led to an increase in test costs for shipping and delayed turnaround times to report the results of the assays. The cost for each single serologic assay to diagnose celiac disease using overseas testing is higher than that of a duodenal biopsy in Korea. High costs and delayed turnaround times may lead to an underutilization of assays to diagnose celiac disease.
patients, resulting in insufficient awareness of the disease during training and clinical practice.

The results of this study offer basic information regarding the utilization of assays in association with celiac disease to improve understanding with regard to the prevalence and incidence of celiac disease based on test utilization of patients with celiac disease in Korea.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
All authors contributed to manuscript preparation; R. Choi, S.G. Lee, and E. H. Lee collected the data or contributed to data analysis; R. Choi and S.G. Lee designed the study; R. Choi, S.G. Lee, and E. H. Lee had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The datasets generated and analyzed during the current study are available from the corresponding authors on reasonable request.

ORCID
Rihwa Choi https://orcid.org/0000-0002-8266-2248
Sang Gon Lee https://orcid.org/0000-0002-4672-5811
Eun Hee Lee https://orcid.org/0000-0002-2517-175X

REFERENCES
1. Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet. 2018;391(10115):70-81.
2. Lombardi C, Savi E, Passalacqua G. Concomitant celiac disease and wheat allergy: 2 case reports. J Investig Allergol Clin Immunol. 2019;29(6):454-456.
3. Singh P, Arora S, Singh A, Strand TA, Makharia GK. Prevalence of celiac disease in Asia: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(6):1095-1101.
4. Husby S, Murray JA, Katzka DA. AGA clinical practice update on diagnosis and monitoring of celiac disease-changing utility of serology and histologic measures: expert review. Gastroenterology. 2019;156(4):885-889.
5. Zhou C, Gao F, Gao J, et al. Prevalence of coeliac disease in Northwest China: heterogeneity across Northern Silk road ethnic populations. Aliment Pharmacol Ther. 2020;51(11):1116-1129.
6. Hokari R, Higashiyma M. Extremely low prevalence of Celiac disease in Japan: eternal silence or just the calm before the storm? JGH Open. 2020;4(4):554-555.
7. Makharia GK, Catassi C. Celiac disease in Asia. Gastroenterol Clin North Am. 2019;48(1):101-113.
8. Gweon TG, Lim CH, Byeon SW, et al. A case of celiac disease. Korean J Gastroenterol. 2013;61(6):338-342.
9. Hwang IK, Kim SH, Lee U, et al. Celiac disease in a predisposed subject (HLA-DQ2.5) with coexisting graves’ disease. Endocrinol Metab (Seoul). 2015;30(1):105-109.
10. Ham H, Lee B-I, Oh HJ, et al. A case of celiac disease with neurologic manifestations misdiagnosed as amyotrophic lateral sclerosis. Intest Res. 2017;15(4):540-542.
11. Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. 2019;7(5):583-613.
12. Lee SW. Significance of duodenal mucosal lesions: can they be a clue to a systemic disease? Korean J Intern Med. 2017;32(5):813-815.
13. National Health Insurance Service. Operational structure of Korea health care system – the governance of Korean health care system. Accessed September 23, 2021. https://www.nhis.or.kr/static/html/wbd/p/a/wbdga0401.html

How to cite this article: Choi R, Lee SG, Lee EH. Underutilization of diagnostic assays for celiac disease in Korea. J Clin Lab Anal. 2021;35:e23913. https://doi.org/10.1002/jcla.23913